Publication Name	World Journal of Clinical Cases
Manuscript ID	77486
Country	China

Received	2022-05-10 13:08
Peer-Review Started	2022-05-10 13:09
To Make the First Decision
Return for Revision	2022-06-27 08:36
Revised	2022-07-16 03:14
Second Decision	2022-08-30 03:19
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2022-08-31 20:06
Articles in Press	2022-08-31 20:06
Publication Fee Transferred
Edit the Manuscript by Language Editor	2022-08-16 13:40
Typeset the Manuscript	2022-09-07 09:23
Publish the Manuscript Online	2022-09-29 09:17

ISSN	2307-8960 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Case Report
Article Title	Immune checkpoint inhibitor-associated arthritis in advanced pulmonary adenocarcinoma: A case report
Manuscript Source	Unsolicited Manuscript
All Author List	Yang Yan and Xiao-Jie Huang
Funding Agency and Grant Number
Corresponding Author	Yang Yan, MM, Associate Chief Physician, Department of Respiratory Medicine, The Second Affiliated Hospital, Zhejiang University School of Medicine, No. 88 Jiefang Road, Hangzhou 310000, Zhejiang Province, China. 163987@zju.edu.cn
Key Words	Immune checkpoint inhibitors; Immune checkpoint inhibitor-associated arthritis; Pembrolizumab; Clinical Disease Activity Index; Case report
Core Tip	We report a severe case of immune checkpoint inhibitor-associated arthritis (IA) in advanced pulmonary adenocarcinoma. A recent study suggested that higher checkpoint inhibitor arthritis disease activity may be associated with cancer progression. In our case, Clinical Disease Activity Index (CDAI) score increased to as high as 43, but cancer disease remained in complete remission 20 mo after the development of IA. Whether CDAI can be a predictor of disease progression needs to be confirmed in future studies.
Publish Date	2022-09-29 09:17
Citation	YanG Y, Huang XJ. Immune checkpoint inhibitor-associated arthritis in advanced pulmonary adenocarcinoma: A case report. World J Clin Cases 2022; 10(29): 10701-10707
URL	https://www.wjgnet.com/2307-8960/full/v10/i29/10701.htm
DOI	https://dx.doi.org/10.12998/wjcc.v10.i29.10701

Full Article (PDF)	WJCC-10-10701.pdf
Full Article (Word)	WJCC-10-10701.docx
Manuscript File	77486_Auto_Edited-YLC-Wang TQ-LS.docx
Answering Reviewers	77486-Answering reviewers.pdf
Audio Core Tip	77486-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	77486-Conflict-of-interest statement.pdf
Copyright License Agreement	77486-Copyright license agreement.pdf
Signed Consent for Treatment Form(s) or Document(s)	77486-Informed consent statement.pdf
Non-Native Speakers of English Editing Certificate	77486-Language certificate.pdf
Peer-review Report	77486-Peer-review(s).pdf
Scientific Misconduct Check	77486-Bing-Chen YL-2.png
Scientific Editor Work List	77486-Scientific editor work list.pdf